NCT01331915View on ClinicalTrials.gov

Safety and Toxicity Study of Vaccination for Advanced Metastatic Melanoma Patients

PHASE1/PHASE2UnknownINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

September 30, 2010

Primary Completion Date

October 31, 2013

Conditions
Melanoma
Interventions
BIOLOGICAL

Theravac

"Three groups with three doses (50 - 150 - 250 mcg), four times every three weeks.~Injection: intradermally and subcutaneously."

Trial Locations (1)

1200

RECRUITING

Cliniques universitaires Saint-Luc, Centre du Cancer, Brussels

Sponsors

Collaborators (1)

Institut Pasteur
All Listed Sponsors
collaborator

Institut Pasteur

INDUSTRY

lead

Cliniques universitaires Saint-Luc- Université Catholique de Louvain

OTHER

NCT01331915 - Safety and Toxicity Study of Vaccination for Advanced Metastatic Melanoma Patients | Biotech Hunter | Biotech Hunter